WO1998005684B1 - Oligomeres peptidiques de liaison cmh et procedes d'utilisation - Google Patents
Oligomeres peptidiques de liaison cmh et procedes d'utilisationInfo
- Publication number
- WO1998005684B1 WO1998005684B1 PCT/US1997/013885 US9713885W WO9805684B1 WO 1998005684 B1 WO1998005684 B1 WO 1998005684B1 US 9713885 W US9713885 W US 9713885W WO 9805684 B1 WO9805684 B1 WO 9805684B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- residues
- oligomer
- mhc
- molecular linker
- flexible molecular
- Prior art date
Links
- 108010066345 MHC binding peptide Proteins 0.000 title claims abstract 57
- 238000000034 method Methods 0.000 title claims abstract 18
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 title claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 20
- 102000043131 MHC class II family Human genes 0.000 claims abstract 12
- 108091054438 MHC class II family Proteins 0.000 claims abstract 12
- 102000043129 MHC class I family Human genes 0.000 claims abstract 9
- 108091054437 MHC class I family Proteins 0.000 claims abstract 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 8
- 230000004913 activation Effects 0.000 claims abstract 6
- 230000002401 inhibitory effect Effects 0.000 claims abstract 4
- 230000003213 activating effect Effects 0.000 claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 17
- 229920000642 polymer Polymers 0.000 claims 16
- 125000000539 amino acid group Chemical group 0.000 claims 15
- 229920001577 copolymer Polymers 0.000 claims 12
- 238000000338 in vitro Methods 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 12
- 230000000890 antigenic effect Effects 0.000 claims 9
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 8
- 230000001270 agonistic effect Effects 0.000 claims 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 230000004962 physiological condition Effects 0.000 claims 6
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims 5
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 5
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 5
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 4
- 102000000503 Collagen Type II Human genes 0.000 claims 4
- 108010041390 Collagen Type II Proteins 0.000 claims 4
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- 102000016202 Proteolipids Human genes 0.000 claims 4
- 108010010974 Proteolipids Proteins 0.000 claims 4
- 108010077895 Sarcosine Proteins 0.000 claims 4
- 229940000635 beta-alanine Drugs 0.000 claims 4
- -1 hydroxy- Chemical class 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 229940043230 sarcosine Drugs 0.000 claims 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims 4
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 3
- 230000001851 biosynthetic effect Effects 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 2
- 150000001299 aldehydes Chemical class 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 229960003646 lysine Drugs 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 235000005985 organic acids Nutrition 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims 2
- 230000000599 auto-anti-genic effect Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Abstract
On décrit des oligomères comprenant au moins deux peptides de fixation du complexe majeur d'histocompatibilité (CMH), joints par une séquence de liaison moléculaire souple. Ces peptides de fixation du CMH peuvent être des peptides de la classe I ou de la classe II. On décrit également un procédé de clonage orienté, destiné à produire de tels oligomères. On peut utiliser les oligomères décrits, par exemple, en rapport avec des procédés destinés à activer ou inhiber de manière spécifique l'activation de lymphocytes T CD4?+ ou CD8+¿. De tels procédés constituent des approches thérapeutiques au traitement de tumeurs, de désordres auto-immuns, de rejet de greffe allogénique et de réactions allergiques.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10508219A JP2000516808A (ja) | 1996-08-05 | 1997-08-05 | Ｍｈｃ結合ペプチドオリゴマーおよび使用方法 |
| CA002262001A CA2262001C (fr) | 1996-08-05 | 1997-08-05 | Oligomeres peptidiques de liaison cmh et procedes d'utilisation |
| EP97938153A EP0917570A2 (fr) | 1996-08-05 | 1997-08-05 | Oligomeres peptidiques de liaison cmh et procedes d'utilisation |
| AU40546/97A AU730477B2 (en) | 1996-08-05 | 1997-08-05 | MHC binding peptide oligomers and methods of use |
| NZ333946A NZ333946A (en) | 1996-08-05 | 1997-08-05 | MHC binding peptide oligomers |
| US09/245,487 US20020058787A1 (en) | 1996-08-05 | 1999-02-05 | Mhc binding peptide oligomers and methods of use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69216796A | 1996-08-05 | 1996-08-05 | |
| US08/692,167 | 1996-08-05 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| WO1998005684A2 WO1998005684A2 (fr) | 1998-02-12 |
| WO1998005684A3 WO1998005684A3 (fr) | 1998-05-14 |
| WO1998005684B1 true WO1998005684B1 (fr) | 1998-06-11 |
| WO1998005684A9 WO1998005684A9 (fr) | 1998-08-06 |
Family
ID=24779521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/013885 WO1998005684A2 (fr) | 1996-08-05 | 1997-08-05 | Oligomeres peptidiques de liaison cmh et procedes d'utilisation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20020058787A1 (fr) |
| EP (1) | EP0917570A2 (fr) |
| JP (1) | JP2000516808A (fr) |
| AU (1) | AU730477B2 (fr) |
| CA (1) | CA2262001C (fr) |
| NZ (1) | NZ333946A (fr) |
| WO (1) | WO1998005684A2 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855316B1 (en) * | 1994-02-14 | 2005-02-15 | University Of Hawaii | Baculovirus produced Plasmodium falciparum vaccine |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| WO2001025277A1 (fr) * | 1999-10-07 | 2001-04-12 | Maxygen Aps | Polypeptides antagonistes a chaine unique |
| US20030100106A1 (en) * | 2000-02-08 | 2003-05-29 | Chang Sandra P. | Baculovirus produced Plasmodium falciparum vaccine |
| WO2009003492A1 (fr) | 2007-07-03 | 2009-01-08 | Dako Denmark A/S | Procédés améliorés pour produire, marquer et utiliser des multimères du cmh |
| JP5010798B2 (ja) | 2001-10-03 | 2012-08-29 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 自己免疫疾患を抑制するためのコポリマー、及びその使用方法 |
| DE10313819A1 (de) * | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| GB2422834B8 (en) * | 2005-02-04 | 2007-01-04 | Proimmune Ltd | MHC oligomer and method of making the same |
| US20090227516A1 (en) * | 2005-11-17 | 2009-09-10 | Ahlstrom Corporation | Compound comprising an autoantigenic peptide and a carrier with a mhc binding motif |
| EP1982176A1 (fr) * | 2006-01-30 | 2008-10-22 | Dako Denmark A/S | Quantification ultra-rapide de lymphocytes-t specifiques d'antigenes dans du sang entier par cytometrie de flux |
| GB2442048B (en) * | 2006-07-25 | 2009-09-30 | Proimmune Ltd | Biotinylated MHC complexes and their uses |
| GB2440529B (en) * | 2006-08-03 | 2009-05-13 | Proimmune Ltd | MHC Oligomer, Components Therof, And Methods Of Making The Same |
| WO2008116468A2 (fr) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Complexes peptidiques du cmh et leurs utilisations dans des maladies infectieuses |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| WO2009114869A2 (fr) * | 2008-03-14 | 2009-09-17 | Cel-Sci Corporation | Procédés de préparation et composition de constructions de peptide utiles pour le traitement de la polyarthrite rhumatoïde |
| WO2010009735A2 (fr) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Analyse et réparation combinatoires |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| KR101873179B1 (ko) * | 2009-08-26 | 2018-06-29 | 셀렉타 바이오사이언시즈, 인크. | Ｔ－세포 도움을 유도하는 조성물 |
| US10179174B2 (en) | 2011-05-25 | 2019-01-15 | Cel-Sci Corp. | Method for inducing an immune response and formulations thereof |
| WO2020054126A1 (fr) * | 2018-09-14 | 2020-03-19 | 国立研究開発法人理化学研究所 | Procédé d'introduction d'une substance dans une cellule cible |
| EP3898666A2 (fr) | 2018-12-17 | 2021-10-27 | Immudex ApS | Panneau comprenant des multimères de borrelia cmh |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194425A (en) * | 1988-06-23 | 1993-03-16 | Anergen, Inc. | Mhc-mediated toxic conjugates useful in ameliorating autoimmunity |
| EP0625200B1 (fr) * | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
-
1997
- 1997-08-05 JP JP10508219A patent/JP2000516808A/ja not_active Ceased
- 1997-08-05 EP EP97938153A patent/EP0917570A2/fr not_active Withdrawn
- 1997-08-05 CA CA002262001A patent/CA2262001C/fr not_active Expired - Fee Related
- 1997-08-05 AU AU40546/97A patent/AU730477B2/en not_active Ceased
- 1997-08-05 WO PCT/US1997/013885 patent/WO1998005684A2/fr not_active Application Discontinuation
- 1997-08-05 NZ NZ333946A patent/NZ333946A/xx unknown
-
1999
- 1999-02-05 US US09/245,487 patent/US20020058787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998005684B1 (fr) | Oligomeres peptidiques de liaison cmh et procedes d'utilisation | |
| AU730477B2 (en) | MHC binding peptide oligomers and methods of use | |
| KR101902029B1 (ko) | 감염성 질환, 자가면역 질환, 동종인자에 대한 면역 반응, 알레르기 질환, 종양, 이식편 거부 및 유전자 요법 또는 유전자 백신접종을 위해 사용되는 바이러스 벡터에 대한 면역 반응의 예방 및/또는 치료에 사용하기 위한 면역원성 펩티드 | |
| WO1998005684A9 (fr) | Oligomeres peptidiques de liaison cmh et procedes d'utilisation | |
| AU775073C (en) | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD | |
| CA2348956A1 (fr) | Procedes immunotherapeutiques utilisant des epitopes de wt-1 et gata-1 | |
| EP0871456A1 (fr) | Compositions pharmaceutiques comportant un copolymere peptidique de synthese et servant a la prevention des troubles dus a la reaction greffe contre hote | |
| NZ281409A (en) | Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls | |
| EP0805162A1 (fr) | Déterminant peptidique associé à l'immunité | |
| NO309798B1 (no) | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen | |
| RU98120519A (ru) | Аутоантиген и структурно-родственные ему белки для применения при иммунотерапии аутоиммунных заболеваний | |
| EP1870418A1 (fr) | Allolimitée peptide spécifiques pour les cellules T | |
| US7053043B1 (en) | Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD | |
| Van der Veen et al. | Immune processing of proteolipid protein by subsets of antigen-presenting spleen cells | |
| Cohen et al. | Exploring the potential of DNA vaccination | |
| Mackewicz et al. | Structural aspects of a protein epitope and their role in the major histocompatibility complex control of T cell responsiveness | |
| Taylor | The mechanism of experimental arthritis produced by streptolysin S | |
| Naor et al. | Antigenic Entities of the Tumor That Induce Suppressor Cells May Prevent the Potentiation of Coexpressed Immunogenic Entities | |
| Breedveld et al. | T-Cell Vaccination—A Prospect | |
| Klein et al. | Antigen Processing: A Reevaluation | |
| Martin | Specific immunomodulation in multiple sclerosis by altered peptide ligands | |
| HK40038219B (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| HK40038219A (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| HK1185886A (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination | |
| HK1185886B (en) | Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination |